OVID News and Press, Ovid Therapeutics Inc. From 10/04/23

2023-10-04 07:14:23 ET Summary Ovid Therapeutics' OV329 shows promise in early Phase 1 data for treating pharmacoresistant epilepsy, boasting superior pharmacokinetics and safety profiles. Financials are strong with a robust current ratio of 10.1 and 24-month cash runway, but cash...

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that it will host a Research & Development (R&...

NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a panel presentat...

NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in two upcoming inves...

2023-08-04 17:35:56 ET Gainers: Atara Biotherapeutics ( ATRA ) +5% . NGM Biopharmaceuticals ( NGM ) +5% . Galera Therapeutics ( GRTX ) +4% . Ovid Therapeutics ( OVID ) +3% . Magnite ( MGNI ) +3% . Losers: Applied Material...

2023-08-04 12:26:04 ET Ovid Therapeutics press release ( NASDAQ: OVID ): Q2 GAAP EPS of -$0.18 beats by $0.03 . Revenue was $75,000 for the three months ended June 30, 2023, as compared to no revenue recognized in the same period of 2022. Total operating expen...

Completed single ascending dose (SAD) portion of Phase 1 trial evaluating OV329, a potential next-generation GABA-aminotransferase inhibitor Executed equity investment and initiated collaboration with Graviton Bioscience to develop highly selective ROCK2 inhibitors for rare neurological c...

NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a fireside chat at...

2023-07-05 10:00:00 ET Summary We've compiled a list of June Investment Picks that you may have missed. Some Seeking Alpha analysts are more discerning by nature. Others are finding compelling ideas hard to come by in today's market environment. The investment ideas featured h...

Dr. Zhong Zhong joins Ovid as Chief Scientific Officer (CSO) and Dr. Manoj Malhotra assumes role as Chief Medical Officer (CMO) following the planned retirement of Dr. Claude Nicaise Meg Alexander promoted to Chief Strategy Officer Ovid streamlined G&A infrastructure to improve oper...